AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease - Cebers, Gvido; Alexander, Robert C; Haeberlein, Samantha Budd; Han, David; Goldwater, Ronald; Ereshefsky, Larry; Olsson, Tina; Ye, Naidong; Rosen, Laura; Russell, Muir; Maltby, Justine; Eketjäll, Susanna; et al. (Journal of Alzheimer's disease, 2017)
Keywords: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - blood; Amyloid beta-Peptides - cerebrospinal fluid; Antipsychotic Agents - pharmacokinetics; Antipsychotic Agents - therapeutic use; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Food; Healthy Volunteers; Humans; Imidazoles - pharmacokinetics; Imidazoles - therapeutic use; Male; Middle Aged; Neurologic Examination; Peptide Fragments - blood; Peptide Fragments - cerebrospinal fluid; Spiro Compounds - pharmacokinetics; Spiro Compounds - therapeutic use; Time Factors; Young Adult; Phase I clinical trials; early onset Alzheimer’s disease; pharmacodynamics; pharmacokinetics; AZD3293; BACE1 protein-human; Amyloid-beta peptides; cerebrospinal fluid proteins